Xylem (NYSE:XYL) Price Target Cut to $99.00 by Analysts at UBS Group

Key Points

• UBS Group cut Xylem’s price target from $112 to $99 and maintained a “neutral” rating, implying roughly 10% upside from the prior close.
• Analyst sentiment is mixed but cautious: Xylem has an average “Hold” rating and a consensus price target of $121.31, while several firms recently lowered targets or downgraded the stock.
• Xylem’s latest quarter fell slightly short of expectations, with $1.44 adjusted EPS and $2.20 billion in revenue; revenue declined 3% year over year amid weaker demand and project-timing pressures.

Xylem (NYSE:XYL - Get Free Report) had its target price reduced by equities researchers at UBS Group from $112.00 to $99.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a "neutral" rating on the industrial products company's stock. UBS Group's price objective points to a potential upside of 9.95% from the company's previous close.

Several other equities research analysts have also issued reports on the company. Wolfe Research began coverage on Xylem in a research note on Tuesday, September 15th. They issued a "peer perform" rating for the company. Robert W. Baird set a $123.00 target price on shares of Xylem in a research note on Wednesday. Stifel Nicolaus lowered their target price on shares of Xylem from $141.00 to $114.00 and set a "buy" rating for the company in a report on Wednesday. Citigroup dropped their price target on shares of Xylem from $148.00 to $130.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, JPMorgan Chase & Co. downgraded shares of Xylem from an "overweight" rating to a "neutral" rating and cut their price target for the company from $118.00 to $90.00 in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $121.31.

Xylem Stock Performance

Xylem stock traded up $1.81 during midday trading on Thursday, hitting $90.04. The stock had a trading volume of 2,955,626 shares, compared to its average volume of 2,162,426. The firm's fifty day moving average is $105.98 and its two-hundred day moving average is $118.05. The company has a market capitalization of $21.02 billion, a PE ratio of 21.41, a P/E/G ratio of 1.75 and a beta of 1.00. Xylem has a 52-week low of $87.40 and a 52-week high of $154.27. The company has a current ratio of 1.61, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23.

Xylem (NYSE:XYL - Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The industrial products company reported $1.44 earnings per share for the quarter, missing the consensus estimate of $1.45 by ($0.01). Xylem had a net margin of 11.15% and a return on equity of 11.77%. The firm had revenue of $2.20 billion for the quarter, compared to analysts' expectations of $2.28 billion. During the same period in the prior year, the firm earned $1.37 EPS. Xylem's revenue for the quarter was down 3.0% compared to the same quarter last year. On average, research analysts forecast that Xylem will post 5.65 EPS for the current year.

Institutional Investors Weigh In On Xylem

A number of institutional investors and hedge funds have recently bought and sold shares of the company. William Mack & Associates Inc. acquired a new position in shares of Xylem in the third quarter valued at approximately $25,000. Dunhill Financial LLC purchased a new stake in shares of Xylem during the second quarter worth approximately $30,000. Avalon Trust Co acquired a new stake in shares of Xylem during the second quarter worth $35,000. Orion Capital Management LLC acquired a new stake in shares of Xylem during the second quarter worth $35,000. Finally, Aventus Investment Advisors Inc. lifted its holdings in shares of Xylem by 66.7% during the second quarter. Aventus Investment Advisors Inc. now owns 300 shares of the industrial products company's stock worth $35,000 after purchasing an additional 120 shares during the period. 87.96% of the stock is owned by institutional investors.

Xylem News Roundup

Here are the key news stories impacting Xylem this week:

• Positive Sentiment: Options activity turned notably bullish on Thursday, with traders purchasing 20,508 call contracts—about 771% above average volume. This may indicate speculative expectations for a rebound, although options activity is not necessarily a fundamental signal.
• Positive Sentiment: Royal Bank of Canada initiated coverage with a “moderate buy” rating and a $125 price target. RBC also reaffirmed its positive view, while Citigroup, BNP Paribas Exane, Oppenheimer and Stifel retained buy or outperform ratings despite lowering their targets. Royal Bank of Canada coverage
• Neutral Sentiment: Xylem announced divestitures and a new three-segment structure as part of a portfolio and operational reset. The changes could improve focus and efficiency, but they also introduce execution risk and signal that management is responding to weaker near-term conditions. Xylem announces divestitures and new structure
• Negative Sentiment: Third-quarter revenue was approximately $2.20 billion, below the roughly $2.28 billion consensus estimate, while adjusted EPS also missed expectations. Revenue fell 3% year over year, with soft metering demand and project timing weighing on sales.
• Negative Sentiment: Management lowered its 2026 revenue and earnings outlook and issued weaker fourth-quarter expectations, citing customer pullbacks and continuing near-term headwinds. The guidance reduction was the primary catalyst for the stock’s decline. Xylem cuts outlook and plans restructuring
• Negative Sentiment: Analyst sentiment has become more cautious: JPMorgan downgraded Xylem to neutral and cut its target to $90, while multiple firms reduced targets, including Stifel to $114 and RBC to $125. Elevated put-option activity on Wednesday also reflected bearish positioning.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to shareholder losses, adding legal and headline risk.

Xylem Company Profile

Xylem Inc NYSE: XYL is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company's products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.